A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide - a ...

Once-weekly cagrilintide–semaglutide combination therapy produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving ≥20% loss and strong cardiometabolic benefits ...

If you’ve been taking Ozempic, Wegovy, or a compounded version of semaglutide, ... Participants saw weight loss by the four-week mark, and this continued for the rest of the experiment.

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with ...

“I think the results are very encouraging, and I hope that industry will take it on and do a regulatory approval trial for semaglutide in type 1,” he added. The 26-week ADJUST-T1D randomized clinical ...

Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...

Oral semaglutide was associated with more pronounced cardiovascular benefits among patients with higher baseline HbA1c in ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the brain. Researchers at Case Western Reserve University found that people ...